NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000001426

Registered date:01/11/2008

Phase I/IIa trial of autologous tumor vaccine and temozolomide administration in patients with primary glioblastoma

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedGlioblastoma
Date of first enrollment2008/10/01
Target sample size25
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Autologous tumor vaccination

Outcome(s)

Primary OutcomeOverall survival
Secondary OutcomeCause-specific survival Progression-free survival Tumor-regression rate, disease-control rate QOL Neurological improvement

Key inclusion & exclusion criteria

Age minimum16years-old
Age maximum75years-old
GenderMale and Female
Include criteria
Exclude criteria1) Patients who have been administered or are taking corticosteroid or anticancer drugs. 2) Patients with high intracranical pressure. 3) Patients with severe myelosupression. 4) Patients with severe complication including hematopathy 5) Patients with malignant tumor or cancer. 6) Pregnant or nursing woman, or woman willing to be pregnant. 7) Patients participate in other study during or within 6 months before temozolomide administration in this study. 8) Other reasons for exclusion

Related Information

Contact

public contact
Name Eiichi Ishikawa
Address Tennodai 1-1-1, Tsukuba, Ibaraki, Japan Japan
Telephone 029-853-3220
E-mail e-ishikawa@md.tsukuba.ac.jp
Affiliation University of Tsukuba Department of Neurosurgery, Doctoral Program in Functional and Regulatory Medical Science, Graduate
scientific contact
Name Eiichi Ishikawa
Address 1-1-1 Tennodai, Tsukuba City, Ibaraki Japan
Telephone 029-853-3220
E-mail e-ishikawa@md.tsukuba.ac.jp
Affiliation University of Tsukuba Department of Neurosurgery, Neurological Institute